Cardiac resynchronization therapy (CRT) is a proven treatment for heart failure and requires the implantation of a left ventricular (LV) lead, usually placed in a tributary of the coronary sinus. Encouraged by the fact that approximately 30 % of the patients receiving CRT do not benefit from this therapy, LV endocardial pacing has been proposed as an alternative to traditional LV transvenous epicardial pacing. Endocardial LV pacing has a number of potential advantages over conventional LV epicardial pacing, including a more physiological endocardial-to-epicardial transmural activation sequence, a faster ventricular activation, a larger choice of stimulation sites and a potential superior hemodynamic performance. On the other hand, cardiologists will have to deal with new implant techniques' (transseptal), higher risk of thromboembolic events, and challenging extraction procedures of infected material. The future of endocardial stimulation will depend on the results of randomized studies adequately powered to assess the feasibility, the safety and the effectiveness of this new pacing strategy.